Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Hepion Pharmaceuticals is a biopharmaceutical company focused on developing therapies for liver diseases, particularly NASH and liver fibrosis. Its lead candidate, rencofilstat, is a cyclophilin inhibitor with potential to treat liver fibrosis, hepatitis, and related conditions. The company advances drug candidates through preclinical and clinical trials, seeking regulatory approval, with no current commercialization capabilities, relying on strategic partnerships and funding to support development.
This description was generated via AI from an annual report. Updated about 1 year ago.